设为首页 加入收藏

TOP

Qutenza179mgcutaneous patch Capsaicin
2014-08-27 22:38:52 来源: 作者: 【 】 浏览:352次 评论:0

For doctors

 

What is it and how is it used?

Qutenza is used to relieve pain in people without diabetes who have nerve pain due to damage in nerves in the skin. Damaged nervesin your skin may occur as a result of a variety of diseases such as shinglesand HIV infection,certain medicinesand other conditions. Qutenzacan be used either alone or in combination with other medicines that you may take to treat your pain.

What do you have to consider before using it?

Do not use Qutenza
·if you are allergic (hypersensitive) to capsaicin, chilli peppers or any other ingredientsinthe Qutenza cutaneous patch(see section 6 at the end of the leaflet)

Take special care with Qutenza

Do not use Qutenzaon any part of your head or face.

Do not use Qutenzaon broken skin or open wounds.

Do not touch Qutenzaor other materials that have come in contact with the treated areas as it may cause burning and stinging. Do not touch your eyes, mouth or other sensitive areas. Sniffing or inhaling close to the Qutenzapatches may cause coughing or sneezing.

Itis usual for the skin to sting or become red and burn during and after Qutenzatreatment for a short while. Because of the pain, your blood pressure may go up and therefore, your doctor will measure your blood pressure several times during your treatment. If you experience a lot of pain, your doctor will apply local cooling or give you medicine for pain.

If you have unstable or poorly controlled high blood pressure or recently had heart problems, your doctor will consider the risk of adverse reactions to your heart or blood pressure due to the potential stress of the procedure before treating you with Qutenza.

If you are using high doses of opioids, you may not respond to oral opioid analgesicswhen used for acute pain during and following the treatment procedure. In this case, your doctor will use other measures to reduce your pain following Qutenza treatment.

Though no changes have been seen in the function of the nerves in patients treated with Qutenza, small, short-term changes in the ability to feel when something is hot or sharp have been seen after use of capsaicin.

Use in children and adolescents

Qutenzais not recommended for treatment in patients under 18years of age.

Using other medicines

Qutenzaacts locally on your skin and is not expected to influence other medicines. Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Pregnancy and breast-feeding

Qutenzashould be used with caution if you are pregnant and/or breastfeeding. If you are pregnant, or think you may be pregnant, or breast-feeding tell your doctor before Qutenzatreatment.

Driving and using machines

There are no studies of the effects of Qutenzaon the ability to drive and use machines. When using Qutenza, only very small amounts of the active substance may be present in the blood stream for a very short time. Therefore, Qutenzais unlikely to have any direct effects on your thinking or your ability to drive or use machinery.

Important information about some of the ingredients of the cleansing gelfor Qutenza

The cleansing gel for Qutenzacontains butylhydroxyanisole which may cause local skin reactions (e.g. contact dermatitis), or irritation of the eyes and mucous membranes.

How is it used?

Qutenzashould only be applied by your doctor or by a nurse under the supervision of your doctor.

Qutenzais for useon your skin.

Your doctor will mark the most painful areas onyour skin with a pen or marker.

Before placing the Qutenzapatches on the skin, the treatment area(s) will be washed with soap and water and dried. Hair in treatment areas will be clipped.

Before placing the Qutenzapatches on the skin, your doctor or nurse will apply a numbing gel or cream to reduce stinging.

Your doctor or nurse will wear gloves to prepare the Qutenzapatches for you. Do not sniff or inhale close to the Qutenzapatches as this may cause coughing or sneezing.
Qutenzamay be cut into smaller pieces to fit the treatment area. No more than 4 patches should be used at the same time. Your doctor or nurse will remove the patches after 30 minutesif you’re being treated for nerve pain on your feetor 60minutes if you’re being treated for nerve pain on other parts of your body. Do not touch the patch with your hands as it may cause burning and stinging.

Usually you will feel some pain relief on the first day the patch is applied. It may take up to 1-14days until the full pain relief of Qutenzatakes effect. If after that time you still have a lot of pain, please talk to your doctor.

Qutenzatherapy may be repeated at 90-day intervals, if necessary.

You may be given pain medicines to take for the pain you experience with Qutenzatherapy.

It is common for the skin to sting or become red and burn during Qutenzatreatment.

Disposable socks may be worn on top of the Qutenzapatches if your feet are being treated.

Sometimes your doctor or nurse may put a bandage on top of the Qutenzapatch to keep the patch firmly on your skin.

At the end of the Qutenzatreatment your doctor or nurse will clean the treated skin with cleansing gel from a tube supplied with the kit.Cleansing gel will be left on your skin for one minute and then wiped off to remove any remaining medicine that may be left on your skin after treatment. After the cleansing gel has been wiped off, the area will be gently washed with soap and water.

Do not touch your eyes, mouth or other sensitive areas.If you accidentally touch the Qutenzapatch or treated skin before cleansing gel is applied it may burn and/or sting. Call your doctor immediately.

Do not attempt to remove the patch yourself. Your doctor or nurse will remove it for you.

Do not take Qutenzapatches away from theclinic.

Do not use Qutenzapatches at home.

If you have any further questions on the use of this product, ask your doctor or pharmacist .

What are possible side effects?

Like all medicines, Qutenza can cause side effects, although not everybody gets them.

The frequency of possible side effects listed below is defined using the following convention:Very common (affects more than 1 user in 10)
Common (affects 1 to 10 users in 100)
Uncommon (affects 1 to 10 users in 1,000)

Very common side effects:

redness, pain on the area where the patch is applie

Common side effects:

itching, bumps, blisters, swelling, dryness on the area where the patch is applie

Uncommon side effects:

wheals, prickling sensation, inflammation of the skin, increased sensitivity, inflammation, skin reaction, irritation, bruising on the area where the patch is applied

high blood pressure, slowing of the electrical signals in the heart, rapid beating of the heart, abnormal awareness of the beating of the heart, decreased taste, reduced sensations in limbs,

burning sensation, eye irritation, cough, throat irritation, nausea, itching, pain in limbs, muscle spasms, shingles, swelling of limbs.

If any of the side effects becomes serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist immediately.

How should it be stored?

Keep out of the reach and sight of children.

Do not use Qutenzaafter the expiry date printed on the carton after EXP. The expiry date refers to the last day of that month.

Qutenza cutaneous patch: Store flat in original sachet and carton. Store below 25°C.

Cleansing gel: Store below 25°C.

After opening sachet, Qutenza should be appliedwithin 2 hours.

Disposal of used and unused Qutenzapatches and socksand gloves.

These items may sting your fingers if you touch them. Your doctor or nurse will put them in a polyethylene bag before safely discarding them. Qutenzapatches and treatment-related materials should be disposed of properly.

↑ back to table of contents ↑

For doctors

What is it?

Qutenza is a cutaneous patch (a patch that delivers a medicine to the skin). It contains the active substance capsaicin (8%).

What is it used for?

Qutenza is used to treat peripheral neuropathic pain (pain that is caused by damage to the nerves) in adults who do not have diabetes. It can be used alone or together with other painkillers. The medicine can only be obtained with a prescription.

How is it used?

Qutenza should be applied by a doctor or by a healthcare professional under the supervision of a doctor. It is applied to the most painful areas of the skin. The painful area should be determined by a doctor and marked on the skin. Qutenza can only be applied to unbroken, non-irritated, dry skin. Patches can be cut to match the area to cover. No more than four patches should be used on the patient at the same time. Before applying Qutenza, the area must be treated with a local anaesthetic, so that it is numbed; this helps to reduce discomfort. Qutenza should remain in place for 30 minutes for the feet and 60 minutes for other parts of the body. Once the patch is removed, the area is cleaned using the cleansing gel provided. It may take between one day and two weeks for Qutenza to have an effect. The treatment may be repeated every three months depending on the patient’s symptoms. Qutenza can cause a burning sensation on the skin. Because of this, healthcare professionals should wear nitrile gloves while applying and removing the patch.

How does it work?

The active substance in Qutenza, capsaicin, is a substance normally found in chilli peppers that is a ‘selective agonist’ of the ‘transient receptor potential vanilloid 1’ (TRPV1) receptor. This means that it stimulates the TRPV1 receptor, which is found in the nociceptors (pain receptors) in the skin. Qutenza contains high doses of capsaicin that are released quickly and overstimulate the TRPV1 receptors. Overstimulating the receptors makes them become ‘desensitised’ and no longer able to respond to the stimuli that normally cause pain in patients with peripheral neuropathic pain.

How has it been studied?

Qutenza has been compared with control patches containing lower amounts of capsaicin (0.04%) in four main studies involving a total of 1,619 adults with moderate to severe neuropathic pain. All of the patients had neuropathic pain due to either post-herpetic neuralgia (pain that occurs in people who have had shingles, an infection caused by the varicella zoster virus) or HIV-associated neuropathy (damage to the nerves caused by HIV infection). The main measure of effectiveness was the reduction in the 24-hour pain score during the eight or 12 weeks period after application of the patch.

What benefits has it shown during the studies?

Qutenza was more effective at reducing neuropathic pain than the control patches. In the two studies of patients with post-herpetic neuralgia, the reduction in pain scores after eight weeks was 30 and 32% in patients who were given Qutenza, compared with 20 and 24% in patients who received the control patches. In one of the studies of patients with HIV-associated neuropathy, patients who were given Qutenza experienced a 23% reduction in pain scores after 12 weeks compared with an 11% reduction in patients who were given the control. In the second study of patients with HIV-associated neuropathy, although Qutenza reduced pain by 30% it was not shown to be more effective than the control.

What is the risk associated?

The most common side effects with Qutenza (seen in more than 1 patient in 10) are pain and erythema (redness) at the site of application. For the full list of all side effects reported with Qutenza, see the Package Leaflet.
Qutenza should not be used in people who may be hypersensitive (allergic) to capsaicin or any of the other ingredients.

Why has it been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Qutenza’s benefits are greater than its risks and recommended that Qutenza be given marketing authorisation.

How has it been studied?

The company that makes Qutenza will make sure that an educational programme is available in all Member States for healthcare professionals who will prescribe Qutenza. The programme will include information on how to administer, handle and dispose of Qutenza and on warnings and precautions that should be taken during treatment.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union for Qutenza on 15 May 2009. The marketing authorisation holder is Astellas Pharma Europe B.V. The marketing authorisation is valid for five years, after which it can be renewed.

↑ back to table of contents ↑
 

Name

 

Qutenza179mgcutaneous patch

 

Composition

 

Each 280cm cutaneous patch contains a total of 179mg of capsaicin or 640micrograms of capsaicin per cm of patch (8% w/w).

Excipient

Each 50g tube of cleansing gelfor Qutenzacontains 0.2mg/gbutylhydroxyanisole (E320).

For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Cutaneous patch.

Each patch is 14cm x 20cm (280cm ) and consists of an adhesive side containing the active substance and an outer surface backing layer. The adhesive side is covered with a removable, clear, unprinted, diagonally cut, release liner. The outer surface of the backing layer is imprinted with ‘capsaicin 8%’.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Qutenza 179mg cutaneous patch 下一篇Qutenza patches (capsaicin)

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位